Brooks Laboratories' Q3 FY 2025-26 Quarterly Results
- 07 Feb 2026
Result Summary
- Brooks Laboratories Ltd reported a 30.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 56.7%.
- Its expenses for the quarter were down by 24.2% QoQ and 56.7% YoY.
- The net profit decreased 31.1% QoQ and decreased 220.4% YoY.
- The earnings per share (EPS) of Brooks Laboratories Ltd stood at 1.87 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 16.69 | 23.84 | 38.55 | -30.0% | -56.7% |
Total Expenses | 16.38 | 21.60 | 37.82 | -24.2% | -56.7% |
Profit Before Tax | 0.30 | 2.24 | 0.72 | -86.6% | -58.3% |
Tax | 0.00 | 0.00 | 0.03 | - | -100.0% |
Profit After Tax | 5.50 | 7.98 | -4.57 | -31.1% | -220.4% |
Earnings Per Share | 1.87 | 2.71 | -1.75 | -31.0% | -206.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Brooks Laboratories Ltd is a company that operates in the pharmaceutical manufacturing industry. The company is primarily involved in the production and distribution of pharmaceutical formulations. Brooks Laboratories focuses on providing a range of drug products, which includes tablets, capsules, injectables, and other pharmaceutical forms. The company serves various segments of the healthcare industry, including both domestic and international markets. As of now, no specific recent major developments about Brooks Laboratories Ltd are available within the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Brooks Laboratories Ltd reported a total income of ₹16.69 crores. When compared to the second quarter of the fiscal year 2026 (Q2FY26), where total income was ₹23.84 crores, there was a quarter-over-quarter (QoQ) decline of 30.0%. Additionally, when compared to the third quarter of the fiscal year 2025 (Q3FY25), where total income was ₹38.55 crores, there was a year-over-year (YoY) decline of 56.7%. These figures reflect a decrease in revenue both on a quarterly and annual basis.
Profitability
The profitability metrics for Brooks Laboratories Ltd during Q3FY26 reflect several changes. The company reported a profit before tax of ₹0.30 crores, which decreased by 86.6% QoQ from ₹2.24 crores in Q2FY26. Compared to Q3FY25, where the profit before tax was ₹0.72 crores, there was a YoY decline of 58.3%. The company did not report any tax expense in Q3FY26, similar to Q2FY26, whereas a tax expense of ₹0.03 crores was reported in Q3FY25, marking a 100.0% YoY decrease. Profit after tax was ₹5.50 crores in Q3FY26, a 31.1% decrease from ₹7.98 crores in Q2FY26, but significantly higher compared to a loss of ₹4.57 crores in Q3FY25, reflecting a YoY change of -220.4%.
Operating Metrics
Key operating metrics for Brooks Laboratories Ltd include earnings per share (EPS), which was ₹1.87 in Q3FY26. This represents a decrease of 31.0% from ₹2.71 recorded in Q2FY26. Compared to Q3FY25, where the EPS was negative at -₹1.75, the YoY change is -206.9%. Total expenses for Q3FY26 amounted to ₹16.38 crores, reflecting a QoQ decrease of 24.2% from ₹21.60 crores in Q2FY26 and a YoY decline of 56.7% from ₹37.82 crores in Q3FY25. These figures indicate changes in the operating costs and income, impacting the overall financial performance metrics of the company.